Cefpirome sulphate is a fourth-generation cephem antibiotic, which has a broad spectrum of antibacterial activity against Gram-positive and -negative bacteria, and is highly stable to ␤-lactamase. Cefpirome sulphate was administered to 166 patients with obstetric or gynaecological infections, and its clinical and antibacterial effect was evaluable in 139. Excluding seven patients who violated the study protocol by receiving concomitant drugs, the safety of cefpirome sulphate was assessed in 159 patients. In the 139 patients in whom efficacy was evaluated, the improvement rate was 80.6% (112/139) and the eradication rate 72.6% (45/62). The eradication rate for bacteria isolated from the patients at the start of the study was 84.7% (111/131). No resistance to cefpirome sulphate was observed in Enterococcus faecalis or Bacteroides species. Systemic erythema and nausea each occurred in one patient, and nine patients showed abnormal hepatic function test results. These results suggest that cefpirome sulphate is effective in the treatment of obstetric and gynaecological infections and has a good side-effect profile.
INTRODUCTION
Cefpirome sulphate (CPR) is a fourthgeneration cephalosporin antibiotic developed jointly by Japan Roussel (currently Hoechst Marion Roussel) and Hoechst Japan (currently Hoechst Marion Roussel). It is an oxime-type cephem with a 2-amino-thiazolylmethoxyimino group in the seventh side-chain, while the third side-chain is modified with cyclopentenopyridine. CPR has a broad spectrum of antibacterial action against Gram-positive and -negative bacteria, especially against the Gram-positive Staphylococcus aureus and S. epidermidis and the Gram-negative Pseudomonas aeruginosa. Immunological tests demonstrate that the drug shows high activity in murine infections caused by various pathogens. 1 -3 Cefpirome sulphate is stable in the presence of various β-lactamases and its protein binding affinity is low. 4 Its plasma half-life after a 1-g intravenous drip infusion was reported to be 1.7 h, and 80 -95% of the drug was excreted unchanged into the urine within 24 h. 5 This drug was approved by the Japanese Ministry of Health and Welfare on condition that its efficacy and antibacterial effect against Enterococcus faecalis and Bacteroides species would be further investigated. We therefore organized a study group to conduct a clinical trial in patients with the relevant obstetric and gynaecological infections, and the results are reported here.
PATIENTS AND METHODS

PATIENT SELECTION
Patients with infections, ranging in age from 16 to 94 years, who presented to the Department of Obstetrics and Gynaecology, Hokkaido University School of Medicine, Sapporo, Japan, and 13 affiliated institutions from September 1995 to March 1999 were enrolled in the study after giving written informed consent. Enrolment criteria were a white blood cell count (WBC) of 8000/mm 3 , C-reactive protein level 0.4 mg/dl, and body temperature of 37°C. Patients in group A had intrauterine infection, adnexitis, parametritis, pelvic peritonitis, Douglas' abscess, or secondary (superficial) infection of surgical wounds, and satisfied at least two of the three enrolment criteria; those with secondary (superficial) infection of surgical wounds had to satisfy either the WBC or CRP criterion. Patients in group B had bartholinitis with symptoms of rubor, swelling or pain on the day of study enrolment.
Patients who had previously received CPR for a different condition, were receiving another antibiotic, did not exhibit symptoms of infection, and did not take CPR for ≥ 3 days were excluded from the study. If it was not clear whether the inclusion criteria were fulfilled, the Case Study Committee investigated the case, with the result that 27 patients were excluded from the study analysis: seven who were concomitantly receiving another antibiotic, 13 in whom the symptoms of infection were not clear, five who had previously received CPR for a different disease, one who did not receive CPR for ≥ 3 days, and one who had a serious underlying disease (stage IVB cervical cancer). Drug efficacy was, therefore, evaluated in 139 patients.
TREATMENT REGIMEN
Patients in both groups received CPR 0.5 -1 g twice daily either by intravenous drip infusion or intravenous injection for ≥ 3 days.
CLINICAL EVALUATION
The clinical effect of CPR was evaluated on a six-point scale as: marked improvement, et al.
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improvement, slight improvement, no change, deterioration, or unevaluable. In cases where patients received both surgical treatment and treatment with antibiotics, we could not differentiate which effects were due to antibiotic treatment and which were due to surgery. Therefore, when any surgical treatment including operation and incision was performed, the clinical effect was evaluated as one point lower on the scale, e.g. as 'improvement' -even if the patient demonstrated 'marked improvement'. Bacteriological testing was done before and after CPR administration. Samples of pus, discharge and fluids from needle biopsies were promptly placed in an anaerobic porter and dispatched to the Tokyo General Laboratory Test Centre (Tokyo, Japan) where bacteria were isolated and identified and the minimum inhibitory concentration (MIC) of CPR was determined. The bacteriological effect was evaluated as: eradication, replacement, decrease, persistent infection or unassessable (unknown).
SAFETY ASSESSMENT
The safety of CPR was assessed in 159 patients since seven patients who took another antibiotic concomitantly were excluded from the safety assessment.
RESULTS
Cefpirome sulphate was administered to 166 patients with obstetric and gynaecological infections; of the 139 patients included in the efficacy analysis, 48 had intrauterine infection, 18 adnexitis, four parametritis, eight bartholinitis, 39 pelvic peritonitis, four Douglas' abscess, and 18 secondary infection of surgical wounds. The disease was considered severe in 27 patients, moderate in 98, mild in 12 and unevaluable in two. Ninety-two patients had underlying disease and complications and 66 had received prior chemotherapy (Table 1) . Table 2 shows the clinical efficacy of CPR by disease type. No patient deteriorated or was unevaluable. The overall improvement rate was 80.6% (112/139 patients). Antibacterial efficacy, defined as eradication plus replacement, was 72.6% (45/62 patients; Table 3 ). Table 4 lists the antibacterial response by isolate. The overall eradication rate of aerobic bacteria was 81.4% and that of anaerobic bacteria was 91.1%. The eradication rate for bacteria isolated from the patients at the start of the study was 84.7% (111/131 patients).
Excluding the seven patients who received other antibiotics, adverse reactions and abnormal changes in test values were investigated in 159 patients. Systemic erythema and nausea occurred in one patient each, but the most common finding was elevated aspartate aminotransferase and alanine aminotransferase levels ( Table 5 ). These enzyme levels returned to normal, however, upon completion of CPR administration.
The MIC of CPR was determined in 137 aerobic and 101 anaerobic bacteria isolated before administration of the drug (Table 6 ). While the MIC in all strains of Escherichia coli was ≤ 0.78 µg/ml, in 90% of the other Gram-negative aerobic bacteria it was ≤ 3.13 µg/ml. Figure 1 compares the MIC for E. faecalis after treatment in our phase IV study with that obtained during drug development. The MIC 50 was 6.25 µg/ml in both cases, while the MIC 90 s were 12.5 and 50 µg/ml, respectively, indicating that no bacteria were resistant to CPR. Among Gram-positive anaerobic bacteria, the MIC in more than 90% ranged from ≤ 0.025 -12.5. The MIC was > 100 µg/ml in only one strain. Among Gram-negative bacteria, including Bacteroides fragilis, Bacteroides species, and Prevotella species, the MIC ranged from et al.
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≤ 0.025 to > 100 µg/ml (Table 6 ). When the MIC of B. fragilis obtained at the time of development was compared with that in this study, the results were similar (Fig. 2) ; the MIC 50 s were 12.5 and 50 µg/ml, respectively, and the MIC 90 was ≥ 100 µg/ml in both cases.
DISCUSSION
Based on the results of this study, the MIC of CPR in 26 strains of E. faecalis was in the range 1.56 -25 µg/ml, and the MIC 50 and MIC 90 were 6.25 µg/ml and 12.5 µg/ml, respectively. The latter two values were reported to be 6.25 µg/ml and 50 µg/ml, respectively, during drug development. 5 No tendency towards resistance to CPR was observed in the E. faecalis strains isolated. The E. faecalis eradication rate in this study was 66.7%. The MIC of CPR in the 14 B. fragilis strains isolated was in the range of 3.13 -> 100 µg/ml, similar to that observed during development. 5 The MIC 50 and MIC 90 were 50 µg/ml and ≥ 100 µg/ml, respectively, compared with 12.5 µg/ml and ≥ 100 µg/ml, respectively, reported during development. 5 The B. fragilis eradication rate was 75.0%. The eradication rates of all Bacteroides species MRSA, methicillin-resistant S. aureus; CNS, coagulase-negative staphylococci; MR-CNS, methicillinresistant CNS; GNR, Gram-negative rods.
TABLE 5
Adverse reactions and abnormal laboratory test findings in patients with obstetric and gynaecological infections after treatment with cefpirome sulphate (n = 159)
Reaction/test finding No. of patients 
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Cumulative susceptibility curve of clinically isolated Enterococcus faecalis in earlier Phase II and III studies (1987-90; ---) compared with the present Phase IV study
FIGURE 1
Cumulative II and III studies (1987-90; ---) compared with the present Phase IV study (1995-99; -) . MIC, minimum inhibitory concentration.
Cumulative susceptibility curve of clinically isolated Bacteroides fragilis in earlier Phase
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and Prevotella species were 80% (eight of 10) and 83.3% (five of six), respectively, and no resistance to CPR was observed in these species. Although the MIC of CPR was not as low in Bacteroides species as in other bacteria, the eradication rate was high because of the biphasic infection that occurs intraperitoneally, i.e. infection with aerobic bacteria (e.g. Escherichia coli) occurs first, reducing the oxidation and reduction potential in the infected tissue, and allowing subsequent infection with anaerobic bacteria. 6 Therefore, effective treatment of intraperitoneal infection requires inhibition of the growth of aerobic bacteria. CPR, which has good antibacterial activity against aerobic bacteria, is useful in the treatment of intraperitoneal infections. The overall improvement rate in the patients in this study was 80.6%. The improvement rate in intrauterine infections was higher at 85.4%, indicating that the drug is clinically effective in obstetric and gynaecological infections.
